A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis.

Tamari, Roni; McLornan, Donal P; Ahn, Kwang Woo; Estrada-Merly, Noel; Hernandez-Boluda, Juan Carlos; Giralt, Sergio A; Palmer, Jeanne M; Gale, Robert Peter; DeFilipp, Zachariah; Marks, David; van der Poel, Marjolein W M; Verdonck, Leo F; Battiwalla, Minoo; Díaz, Miguel A; Gupta, Vikas; Ali, Haris; Litzow, Mark R; Lazarus, Hillard M; Gergis, Usama; Bashey, Asad; ... (2023). A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood advances, 7(15), pp. 3993-4002. American Society of Hematology 10.1182/bloodadvances.2023009886

[img] Text
bloodadvances.2023009886.pdf - Accepted Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (423kB) | Request a copy

To develop a prognostic model for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT) for myelofibrosis (MF). We examined 623 patients undergoing allo-HCT between 2000 - 2016 in the USA (CIBMTR cohort). A Cox multivariable model was used to identify factors prognostic of mortality. A weighted score using these factors was assigned to patients transplanted in Europe (EBMT cohort) (n = 623). Age above 50 (hazard ratio [HR], 1.39; 95% confidence interval [CI], 0.98 -1.96), and HLA matched unrelated donor (HR, 1.29; 95% CI, 0.98-1.7) were associated with increased hazard of death and were assigned 1 point. Hemoglobin lower than 100g/L at time of transplant (HR, 1.63; 95% CI, 1.2- 2.19), and a mismatched unrelated donor (HR, 1.78; 95% CI, 1.25- 2.52), were assigned 2 points. The 3-year overall survival (OS) in patients with a low (1-2 points), intermediate (3-4 points) and high score (5 points) were 69% (95% CI, 61% -76 %), 51 % (95% CI, 46% -56.4 %), and 34% (95% CI, 21% - 49%), respectively (P. < 0.001). Increasing score was predictive of increased transplant related mortality (TRM) (P .0017) but not for relapse (P. 0.12). The derived score was predictive for OS (P. < 0.001) and TRM (P. 0.002) but not relapse (P. 17) in the EBMT cohort as well. The proposed system was prognostic of survival in two large cohorts, CIBMTR and EBMT, and can easily be applied by clinicians consulting patients with MF on transplant outcomes.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Bacher, Vera Ulrike


600 Technology > 610 Medicine & health




American Society of Hematology




Pubmed Import

Date Deposited:

04 May 2023 08:05

Last Modified:

29 Jul 2023 00:13

Publisher DOI:


PubMed ID:






Actions (login required)

Edit item Edit item
Provide Feedback